Chinese hospital market medication report in the third quarter of 2014

Source: Xinkangjie, December 16, 2014, Q3, China's pharmaceutical market scale (based on the retail price) for hospitals above the second level was 246.8 billion yuan, an increase of 22.2% year on year Please refer to the text for the category, manufacturer and single product ranking According to the overall market performance of Zhongkang CMH, in Q3 of 2014, the drug market scale of national hospitals above the second level (based on the retail price) was 246.8 billion yuan, a year-on-year increase of 22.2% - the highest year-on-year growth rate in the first three quarters of 2014, but in fact, Q3 only increased 1.5% month on month compared with Q2, so the high growth rate in the quarter was more due to Q3 of 2013 's market is smaller, not a sign of recovery In fact, compared with the first three quarters of 2013, the market size in the first three quarters of 2014 increased by 17.4% year on year In Q3 2014, the market scale of chemical drugs was RMB 1973 billion, and that of Chinese patent medicine was RMB 47 billion The proportion of Chinese patent medicine rose to the highest level since 2013, accounting for 19.1% As a whole, in the first three quarters of 2014, the growth rate of market scale of Chinese patent medicine was higher than that of chemical medicine, with the former increasing by 21.9% year-on-year and the latter by 16.4% year-on-year From the perspective of channels, the growth rate of urban level hospitals was slightly higher than that of county level hospitals in the first three quarters of 2014, with a year-on-year growth of 17.5% and 16.9% respectively In Q3 2014, city level hospitals accounted for 76.7% of the national drug market share of hospitals above the second level In Q3 2014, the sales volume was 189.2 billion yuan, while county level hospitals only accounted for 23.3% of the market share, and the sales volume was 57.6 billion yuan The scale pattern of drug market in tertiary hospitals and secondary hospitals is basically consistent with Q1 and Q2 In Q3 2014, the scale of drug market in tertiary hospitals in China was 1434 billion yuan, while the scale of drug market in secondary hospitals was 103.4 billion yuan The proportion of tertiary hospitals in the drug market of hospitals above the second level is slightly lower than the overall level of the first three quarters, 58.1% (58.2% in the first three quarters), but the growth rate of tertiary hospitals' market scale in the first three quarters of 2014 is faster, with a year-on-year growth of 19.3%, 4.5 percentage points higher than that of secondary hospitals Prescription drugs continue to occupy an absolute advantage in the hospital market In Q3 2014, 94.2% of the prescription drugs in the second-class and above hospitals nationwide accounted for, and the market scale reached RMB 232.5 billion In Q3 2014, multinational enterprises and local enterprises performed well The top 10 enterprises with the highest sales volume in the drug market of hospitals above the second level continued to be consistent with Q1 and Q2, but the ranking of four enterprises changed What has changed most is that the local enterprise Yangzijiang pharmaceutical industry has become the champion with a market scale of 5.1 billion yuan, an increase of 10.3% on a month on month basis - this is that Yangzijiang has been growing by more than 10% on a month on month basis for two consecutive quarters In the first three quarters of 2014, the growth rate of Yangtze River was the fastest among top 10 enterprises, with a year-on-year growth of 28.2% Pfizer, a multinational pharmaceutical company, came second with a market size of 5 billion yuan, with a year-on-year growth of 25.8% in the first three quarters AstraZeneca followed closely with a market size of 4.9 billion yuan, with a year-on-year growth of 22.8% in the first three quarters In addition, Sanofi Q3 increased by 15.9% on a month on month basis, which is the fastest growth among the top 10 enterprises The market scale reached 4.1 billion yuan, surpassing Bayer healthcare and returning to the fourth place In Q3 of 2014, the top 10 enterprise categories and single products in the sales volume of drugs in the national secondary hospitals and above continued to grow at a low level under the influence of the anti infective drug restriction order By Q3 of 2014, they had been surpassed by cardiovascular system drugs and were no longer the largest category With a year-on-year growth rate of 17.1% in the first three quarters, cardiovascular system drugs have become the largest category, with a market scale of 42.6 billion yuan in Q3 in 2014 However, the fastest growing category is anti-tumor and immunomodulator, with a year-on-year growth of 35.9% in the first three quarters In 2014, the market size of Q3 has reached 31.4 billion yuan In terms of single products, the market pattern has also changed a lot In the first two quarters, the champion single Xueshuantong showed a negative growth, down 5.3% year-on-year and 12.5% month on month In addition, Shuanglu complex coenzyme was the single product with the highest year-on-year growth in the first three quarters of 2014, accounting for 41.5% In 2014, Q3 market scale was 1.4 billion yuan, becoming the second largest single product in the drug market sales of the second-class and above hospitals in China Another fast-growing single product is Xiyanping, with a year-on-year growth of 41.1% in the first three quarters of 2014, but only a 3.0% increase in Q3 in 2014 Therefore, compared with Q2, its ranking has declined by one place However, although the ring ratio of Q3 of beiqingxing is slightly lower, the year-on-year growth of the first three quarters is still 28.2%, and the ring ratio decline may be a seasonal rule.